PPI-1019 Uses, Dosage, Side Effects and more
Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.
| Trade Name | PPI-1019 |
| Generic | PPI-1019 |
| Type | |
| Formula | C36H54N6O5 |
| Weight | Average: 650.865 Monoisotopic: 650.415568863 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in alzheimer's disease.
How PPI-1019 works
PPI-1019 (Apan) inhibits the aggregation of
beta-amyloid and its associated nerve cell toxicity. In addition, Apan reaches the brain in quantities that are sufficient to
block the aggregation of beta-amyloid molecules and alter the course of the disease.
Accumulation of beta-amyloid in the brain is often thought of as a defect in the ability to clear beta-amyloid from the brain through the cerebral spinal fluid (CSF). Both humans and transgenic mice with Alzheimer's disease plaques show increased levels of beta-amyloid in the brain and decreased levels in the CSF. Transgenic mice treated with Apan show significant increases in beta-amyloid levels in the CSF, indicating that Apan is able to mobilize beta-amyloid in the brain and may be facilitating its clearance.
